The year 2004 marks the ”ftieth anniversary of the celebrated 1954 Salk polio vaccine trial. This enormous clinical trial, involving 1.8 million children, was carried out with the co-operation and assistance of hundreds of thousands of lay volunteers, along with medical professionals and local health departments throughout the USA. While the trial was an impressive public health achievement, ”rmly establishing the ef”cacy of the killed virus vaccine and paving the way for eradication of the disease, it was not without controversy. This article recounts the story of this important early clinical trial and how the social and political conditions at the time affected its planning and execution.
Get full access to this article
View all access options for this article.
References
1.
McMichael AJ, Hanke T. HIV vaccines 1983–2003. Nat Med2003; 9: 874–80.
2.
Benison S. Tom Rivers: reflections on a life in medicine and science. Boston: MIT Press, 1967.
3.
De Kruif P. Activities of the NFIP in the field of virus research. New York: National Foundation for Infantile Paralysis, Inc., 1939.
4.
Carter R. Breakthrough: the saga of Jonas Salk. New York: Trident Press, 1966.
5.
New York Times, Nov 21, 1951. $4,000,000 sought in polio drive here.
6.
New York Times, June 3, 1952. Record polio donations.
7.
National Foundation for Infantile Paralysis. Annual Reports 1951–1955.
8.
Deignan LD, Miller E. The support of research in medical and allied fields for the period 1946 through 1951. Science1952; 115: 321–43.
9.
Berk LB. Polio vaccine trials of 1935. Trans Coll Phys Philadelphia1989; 11: 321–36.
10.
Paul J. History of poliomyelitis. New Haven: Yale University Press, 1971.
11.
Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science1949; 109: 85–87.
12.
Morgan IM. Level of serum antibody associated with intracerebral immunity in monkeys vaccinated with Lansing poliomyelitis virus. J Immunol1949; 62: 301–10.
13.
Salk JE. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health44: 563–70.
14.
Smith JS. Patenting the sun. New York: William Morrow,1990.
15.
Meier P.Safety testing of poliomyelitis vaccine. Science1957; 125: 1067–1071.
16.
Salk JE. Studies in human subjects on active immunization against poliomyelitis. JAMA1953; 151: 1081–1098.
17.
Meldrum ML. “Departures from the design”: the randomized clinical trial in historical context, 1946– 1970. PhD Thesis, State University of New York at Stonybrook, 1994.
18.
Francis T.Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine: Final Report. Ann Arbor: Edward Brothers, Inc, 1957.
19.
New York Times, April 5, 1955. Health units call polio vaccine safe.
20.
Vaccine Evaluation Center, University of Michigan. Evaluation of 1954 Field Trial of Poliomyelitis Vaccine. Summary Report. April 12, 1955. Ann Arbor, Michigan.
21.
Advisory Committee on Human Radiation Experiments. Final Report. Washington, DC: US Government Printing Of”ce, 1995: 113–114.
22.
Brownlee KA. Statistics of the 1954 polio vaccine trials. J Am Stat Assoc1955; 50: 1005–1013.
23.
US Public Health Service. Technical Report on Salk Poliomyelitis Vaccine and Report on vaccine Produced by the Cutter Laboratories. US Department of Health, Education and Welfare, 1955.
24.
Kapikian AZ. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Symposium 238: Gastroentereisis Viruses. John Wiley and Sons, 2001.
25.
Pollak M.Doctors ” ghting backlash over vaccines. New York Times, April 27, 1999.
26.
Williams, L.The most worrisome risks deserve the least attention. Baltimore Sun, September 28, 2003.
27.
Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science2003; 301: 804-804.
28.
Scott EC. The National Childhood Vaccine Injury Act turn ” fteen. Food Drug Law J2001; 56: 351–365.
